Patient treatment preference does not affect outcomes in treatment-resistant depression, secondary analysis finds

This secondary analysis of a randomized controlled trial examined the relationship between patient treatment preference and clinical outcomes in 256 patients with treatment-resistant depression (TRD) who were on stable antidepressant therapy. Patients were categorized based on whether they received their preferred treatment, had no preference, or received treatment against their preference. The primary comparison was between these preference groups.

The main outcome was change in Montgomery-Asberg Depression Rating Scale (MADRS) score. Results showed similar changes in MADRS scores among patients who received their preferred treatment, those with no preference, and those who received treatment against their preference (P=0.49). No specific effect sizes or absolute numbers were reported for this comparison. The analysis found no significant association between patient preference and treatment response.

Safety and tolerability data were not reported for this secondary analysis. Key limitations include the study's design as a secondary analysis, which may have limited statistical power and was not pre-specified as a primary outcome. The P-value of 0.49 indicates no significant relationship between preference and outcome.

For clinical practice, this analysis suggests that patient treatment preference alone may not be a significant factor in predicting optimal treatment outcomes for TRD patients. However, clinicians should recognize this as an association from secondary data rather than evidence of causation. The findings should be considered alongside other clinical factors when making treatment decisions with patients.